ReviewFrontiers in cellular and infection microbiology2013
Laboratory diagnosis of persistent human chlamydial infection.
Review in Frontiers in cellular and infection microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Clinical characteristics of Chlamydia pneumoniae pneumonia in 145 children: a single-centre retrospective study.Frontiers in pediatrics · 2026Article
- Article
- Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Review
- Combination of Individual Tests to Improve Diagnostic Accuracy inMedicina (Kaunas, Lithuania) · 2025Article
- Atypical pneumonia (Review).Experimental and therapeutic medicine · 2024Review
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Are ELISA and PCR Discrepancies in the Identification ofMicroorganisms · 2023Article
- Serum antibodies to surface proteins ofFEMS microbes · 2022Article
- Reliable and Sensitive Nested PCR for the Detection ofMicroorganisms · 2021Article
- Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection.Pharmaceutics · 2020Article
- Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology.Scientific reports · 2019Article
- Article
- Comprehensive Molecular Serology of HumanmSphere · 2018Article
- Discovery of Human-Specific ImmunodominantmSphere · 2018Article
- Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.Clinics in chest medicine · 2017Review
- The role of viable but non-infectious developmental forms in chlamydial biology.Frontiers in cellular and infection microbiology · 2014Article
- The Use of Guidelines for Lower Respiratory Tract Infections in Tanzania: A Lesson from Kilimanjaro Clinicians.Annals of medical and health sciences researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic assays for persistent chlamydial infection are much needed to conduct high-quality, large-scale studies investigating the persistent state in vivo, its disease associations and the response to therapy. Yet in most studies the distinction between acute and persistent infection is based on the interpretation of the data obtained by the assays developed to diagnose acute infections or on complex assays available for research only and/or difficult to establish for clinical use. Novel biomarkers for detection of persistent chlamydial infection are urgently needed. Chlamydial whole genome proteome arrays are now available and they can identify chlamydial antigens that are differentially expressed between acute infection and persistent infection. Utilizing these data will lead to the development of novel diagnostic assays. Carefully selected specimens from well-studied patient populations are clearly needed in the process of translating the proteomic data into assays useful for clinical practice. Before such antigens are identified and validated assays become available, we face a challenge of deciding whether the persistent infection truly induced appearance of the proposed marker or do we just base our diagnosis of persistent infection on the presence of the suggested markers. Consequently, we must bear this in mind when interpreting the available data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.